Payment overview · 2025
General Payments
$343.21
14 reported records · 9 companies
Healthcare provider profile · identity verified
John Bisbee Johnson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BATESVILLE, IN · NPI 1790709103
Verified facts
What the public records show
CMS Open Payments records show John Bisbee Johnson, MD received $343.21 in general payments during 2025 across 14 reported records.
Lilly USA, LLC accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Paxlovid.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $117.36 | 34.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.73 | 20.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.22 | 12.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.27 | 6.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.08 | 6.1% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $19.70 | 5.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.76 | 5.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.22 | 5.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.87 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $343.21 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $117.36 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.67 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.77 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.22 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 215 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
215 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 359 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 292 | 54 |
| Furosemide | Furosemide | 248 | 38 |
| Eliquis | Apixaban | 215 | 30 |
| Lisinopril | Lisinopril | 197 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 190 | 35 |
| Losartan Potassium | Losartan Potassium | 166 | 24 |
| Gabapentin | Gabapentin | 162 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 34 |
| Omeprazole | Omeprazole | 159 | 36 |
| Metformin Hcl | Metformin Hcl | 157 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 153 | 25 |
| Potassium Chloride | Potassium Chloride | 147 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 18 |
| Sertraline Hcl | Sertraline Hcl | 113 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 19 |
| Donepezil Hcl | Donepezil Hcl | 99 | 16 |
| Allopurinol | Allopurinol | 93 | 20 |
| Famotidine | Famotidine | 91 | 11 |
| Carvedilol | Carvedilol | 87 | 12 |
| Warfarin Sodium | Warfarin Sodium | 86 | suppressed |
| Meloxicam | Meloxicam | 83 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 18 |
| Trazodone Hcl | Trazodone Hcl | 76 | 17 |
| Glimepiride | Glimepiride | 74 | 16 |
| Simvastatin | Simvastatin | 72 | 14 |
| Montelukast Sodium | Montelukast Sodium | 67 | 12 |
| Prednisone | Prednisone | 65 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 14 |
| Xarelto | Rivaroxaban | 61 | suppressed |
| Torsemide | Torsemide | 60 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 26 |
| Levetiracetam | Levetiracetam | 56 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Celecoxib | Celecoxib | 52 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Finasteride | Finasteride | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 13 |
| Spironolactone | Spironolactone | 47 | suppressed |
| Atenolol | Atenolol | 46 | suppressed |
| Levofloxacin | Levofloxacin | 46 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 21 |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 16 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Kerendia | Finerenone | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | 14 |
| Diltiazem 12hr Er | Diltiazem Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Primidone | Primidone | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Cephalexin | Cephalexin | 19 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | 12 |
| Humalog | Insulin Lispro | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Arformoterol Tartrate | Arformoterol Tartrate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 14 | 11 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $343.21 · 14 records | Lilly USA, LLC | CRENESSITY, ELIQUIS, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, PAXLOVID, QUTENZA, REPATHA, REXULTI, VRAYLAR, Veozah, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error